CXCL16 and asthma: In accordance with the in vitro demonstrated capacity of recombinant CXCL16 to induce chemotaxis of lung tissue-derived murine ILC2s, antibody-mediated in vivo neutralization of CXCL16 was able to successfully dampen the pulmonary accumulation of ILC2s in the context of experimentally induced asthma (137).